Diabetes News and Research

Latest Diabetes News and Research

Advanced BioHealing commences efficacy trial of Dermagraft in the treatment of VLUs

Advanced BioHealing, Inc. (ABH), a leader in commercializing the promise of regenerative medicine, announced that it has initiated a pivotal trial of Dermagraft® in subjects with venous leg ulcers (DEVO-Trial) to assess the product’s safety and efficacy in the promotion of healing venous leg ulcers (VLUs). Dermagraft is a bio-engineered skin substitute that assists in restoring damaged tissue and supports the body’s natural healing process.

17 Nov 2009

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Alkermes, Inc. today announced the initiation of a phase 2 clinical study of ALKS 33, an investigational oral opioid modulator for the potential treatment of alcohol dependence and other central nervous system disorders. The study will assess the safety and efficacy of multiple doses of ALKS 33 in patients with alcohol dependence and is designed to further define the clinical profile of ALKS 33.

17 Nov 2009

Recent developments at Burnham Institute for Medical Research

New antibiotics for methicillin-resistant Staphylococcus aureus (MRSA) and other pesky bacteria. Andrei Osterman and collaborators have used comparisons of bacterial genomes to identify new targets for antibiotics and produced first-generation chemical inhibitors of a class of bacterial enzymes, called NadDs (nicotinate mononucleotide adenylyltransferases).

17 Nov 2009

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

An alliance of institutions collectively managing an estimated 80 percent of all public health research funding worldwide today announced their first targets for concerted action in the fight against "chronic non-communicable diseases" (CNCDs).

17 Nov 2009

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

deCODE genetics, Inc. (Nasdaq: DCGN) today announced that it has filed a voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code with the United States Bankruptcy Court for the District of Delaware to facilitate the sale of substantially all of its assets. deCODE is continuing to operate its business and manage its properties as a debtor-in-possession pursuant to Sections 1107 and 1108 of the Bankruptcy Code.

17 Nov 2009

Play video games to prevent or improve obesity and lifestyle-related disease

Active Wii sports- video games and some Wii fit- activities may increase adults' energy expenditure as much as moderately intense exercise, according to research presented at the American Heart Association's Scientific Sessions 2009.

17 Nov 2009

Program for childhood cancer survivors to quit smoking

As smokers nationwide struggle to quit the habit, St. Jude Children's Research Hospital is offering assistance to those childhood cancer survivors who need help with smoking cessation.

17 Nov 2009

Roche receives EUA from FDA for its RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 virus

Roche`s RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 influenza virus has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA). The Roche kit detects RNA from the 2009 H1N1 influenza A virus and allows rapid and accurate identification of patients infected with this virus.

17 Nov 2009

Nutrition is crucial to achieve the most desirable complexion

Researchers from the universities of Bristol and St. Andrews in the UK have found that the color of a person's skin affects how healthy and therefore attractive they appear, and have found that diet may be crucial to achieving the most desirable complexion. The work will be published in the December issue of Springer's International Journal of Primatology.

17 Nov 2009

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

Scientists at the University of Pennsylvania School of Medicine discovered that a dietary antioxidant found in such vegetables as broccoli and cauliflower protects cells from damage caused by chemicals generated during the body's inflammatory response to infection and injury. The finding has implications for such inflammation-based disorders as cystic fibrosis (CF), diabetes, heart disease, and neurodegeneration.

17 Nov 2009

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

A protein long thought to be a secondary regulator in the heart's response to stressors like hypertension actually appears to be a primary regulator according to researchers from the Center for Translational Medicine at Thomas Jefferson University.

17 Nov 2009

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

NovaDel Pharma Inc. today announced its entry into an exclusive license and distribution agreement with ECR Pharmaceuticals Company, Inc., a wholly owned subsidiary of Hi-Tech Pharmacal Co., Inc. to commercialize and manufacture ZolpiMist™ in the United States and Canada. ZolpiMist™ is our oral spray formulation of zolpidem tartrate approved by the FDA in December of 2008.

16 Nov 2009

Update from Novo Nordisk regarding its share repurchase programme

On 7 August 2009 Novo Nordisk initiated its share repurchase programme in accordance with the provisions of the European Commission's regulation no 2273/2003 of 22 December 2003, also referred to as the Safe Harbour rules.

16 Nov 2009

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Sciele Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd. and Addrenex Pharmaceuticals, Inc., a privately-held U.S. pharmaceutical company specializing in developing drugs that regulate the adrenergic system, today announced that Sciele has agreed to acquire Addrenex.

16 Nov 2009

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Hollis-Eden Pharmaceuticals, Inc., today reported preliminary results of its ongoing Phase I/II clinical trial with Apoptone® (HE3235) for hormone-resistant prostate cancer (also called castrate-resistant prostate cancer or CRPC). Presented at the Molecular Targets and Cancer Therapeutics Conference, which is co-sponsored by the AACR, NCI and EORTC, the poster is titled: "Results of preclinical and clinical Phase I/II open-label dose-ranging trial with HE3235, a synthetic adrenal hormone, in Castrate Resistant Prostate Cancer (CRPC)."

16 Nov 2009

Lotus Pharmaceuticals reports $5.4 million net earnings for third-quarter 2009

Lotus Pharmaceuticals, Inc. a growing developer and producer of prescriptions drugs and licensed national seller of pharmaceutical products in the People's Republic of China, today reported third-quarter 2009 net earnings were $5.4 million, or $0.11 per diluted share, compared with $3.2 million, or $0.07 per diluted share, in 2008. Net revenues were $14.5 million during the third quarter of 2009, compared with $16.7 million in the third quarter of 2008.

16 Nov 2009

Color of skin impacts health, say researchers

16 Nov 2009

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Alkermes, Inc. today announced positive preliminary results from a phase 3 clinical trial of naltrexone for extended-release injectable suspension (XR-NTX) for the treatment of opioid dependence. The six-month phase 3 study met its primary efficacy endpoint and data showed that patients treated once-monthly with XR-NTX demonstrated statistically significant higher rates of clean (opioid-free) urine screens, compared to patients treated with placebo, as measured by the cumulative distribution of clean urine screens (p<0.0002).

16 Nov 2009

Mayo Clinic Health Letter provides treatment options for people with heart disorders

Fewer than one-third of patients with heart failure are taking the three types of medications that are most effective in prolonging life and improving quality of life. The November issue of Mayo Clinic Health Letter provides an overview of treatments recommended by national guidelines.

16 Nov 2009

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Human Genome Sciences, Inc. today announced that it has received a Complete Response Letter from the U.S. Food and Drug Administration (FDA) relating to the Company’s Biologics License Application (BLA) requesting the approval of raxibacumab for use in the treatment of inhalational anthrax. The FDA issues Complete Response Letters to request additional information needed to complete the review of a BLA.

16 Nov 2009

Diabetes News and Research

Latest Diabetes News and Research

Advanced BioHealing commences efficacy trial of Dermagraft in the treatment of VLUs

Alkermes commences phase 2 study of ALKS 33 in patients with alcohol dependence

Recent developments at Burnham Institute for Medical Research

Global Alliance for Chronic Disease to fight against chronic non-communicable diseases

deCODE genetics files voluntary petition for relief under Chapter 11 of the United States Bankruptcy Code

Play video games to prevent or improve obesity and lifestyle-related disease

Program for childhood cancer survivors to quit smoking

Roche receives EUA from FDA for its RealTime ready Influenza A/H1N1 Detection Set for the 2009 H1N1 virus

Nutrition is crucial to achieve the most desirable complexion

Antioxidant found in vegetables can protect cells from damage caused by infection and injury

GSK-3alpha protein: A potent, positive regulator of cardiac hypertrophy

ECR Pharmaceuticals to commercialize and manufacture ZolpiMist in the U.S. and Canada

Update from Novo Nordisk regarding its share repurchase programme

Addrenex Pharmaceuticals to be acquired by Sciele Pharma

Interim data from Hollis-Eden Pharmaceuticals' Apoptone Phase I/II clinical trial presented

Lotus Pharmaceuticals reports $5.4 million net earnings for third-quarter 2009

Color of skin impacts health, say researchers

Alkermes' phase 3 trial of naltrexone XR-NTX meets primary endpoint

Mayo Clinic Health Letter provides treatment options for people with heart disorders

FDA issues a Complete Response Letter for Human Genome Sciences' raxibacumab BLA

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Diabetes News and Research

Latest Diabetes News and Research

Synthetic Biology and the Pursuit of Living Diagnostics

Modular, Scalable, Intelligent: How n6 Is Rethinking NGS Library Prep

Shaping the future of lab automation through AI and robotics

Newsletters you may be interested in